依那普利联合吲达帕胺治疗稳定型冠心病合并高血压疗效观察  

Effect of enalapril combined with indapamide on stable coronary heart disease and hypertension

作　　者：张怡 段宏[1] 唐莉 王永伟 Zhang Yi;Duan Hong;Tang Li(Department of Hypertension,Xihua County People's Hospital,Zhoukou466600,China)

机构地区：[1]西华县人民医院高血压科,河南周口466600 [2]西华县人民医院心内科,河南周口466600

出　　处：《华北理工大学学报（医学版）》2023年第4期288-293,共6页Journal of North China University of Science and Technology：Health Sciences Edition

摘　　要：目的分析依那普利联合吲达帕胺治疗稳定型冠心病合并高血压的疗效。方法选取2019年2月~2022年2月在我院治疗的126例稳定型冠心病合并高血压患者为研究对象,根据随机数字表法分为依那普利组(对照组)、联合治疗组(观察组),每组各63例,前者采用依那普利治疗,后者在其基础上联合吲达帕胺治疗,比较收缩压(SBP)、舒张压(DBP)水平;采用酶联免疫吸附法检测单核细胞趋化蛋白-1(MCP-1)、心肌型脂肪酸结合蛋白(H-FABP)、可溶性ST2(sST2)、基质金属蛋白酶-9(MMP-9)、内皮素-1(ET-1)及一氧化氮(NO)、白细胞介素-6(IL-6)水平,比较两组治疗效果及不良反应。结果与对照组比较,观察组血压水平较低(t=9.696、7.980),MCP-1、H-FABP、sST2水平较低(t=16.020、17.010、23.140),MMP-9、ET-1及IL-6水平较低,(t=6.061、13.090、7.598、11.990),差异均有统计学意义(P<0.05),总不良反应发生率较低,(χ^(2)=4.881);治疗总有效率较高(χ^(2)=6.914),差异有统计学意义(P<0.05)。结论依那普利联合吲达帕胺在冠心病高血压治疗中可改善患者临床症状、促进血压水平恢复正常,降低MMP-9、ET-1及IL-6水平,药物安全性高。Objective Effect of enalapril combined with indapamide in the treatment of stable coronary heart disease with hypertension.Methods 126 patients with stable coronary heart disease and hypertension were treated in our hospital from February 2019 to February 2022.They were divided into enalapril group and combined treatment group according to the random number table method,with 63 patients in each group.The former was treated with enalapril alone,and the latter was treated with indapamide on the basis of the former.The standard mercury mercury column was used to measure the level of systolic and diastolic blood pressure;The levels of monocyte chemoattractant protein-1(MCP-1),cardiac fatty acid-binding protein(H-FABP),soluble ST2(sST2),MMP-9,ET-1,inflammatory factors nitric oxide(NO),interleukin-6(IL-6)were detected by enzyme-linked immunosorbent assay,and the therapeutic effects and adverse reactions were statistically analyzed and compared.Results Compared with the enalapril group,the combined treatment group had lower blood pressure levels,the differences were statistically significant(t=9.696,7.980,P<0.05),had lower levels of MCP-1,H-FABP,and sST2,the differences were statistically significant(t=16.020,17.010,23.140,P<0.05),had lower levels of MMP-9,ET-1,and inflammatory factors,the differences were statistically significant(t=6.061,13.090,7.598,11.990,P<0.05),and had lower total adverse reactions,the differences was statistically significant(χ^(2)=4.881,P<0.05);The total effective rate of the combined treatment group was higher,the differences was statistically significant(χ^(2)=6.914,P<0.05).Conclusion Enalapril combined with indapamide has an ideal effect in the treatment of coronary heart disease and hypertension,which can effectively reduce the levels of MMP-9 and ET-1,and has a high drug safety.

关 键 词：依那普利 吲达帕胺 冠心病高血压 基质金属蛋白酶-9 内皮素-1 

分 类 号：R544.1[医药卫生—心血管疾病] R541.4[医药卫生—内科学]